177943-88-3

177943-88-3 structure

Name: DOTATATE
Chemical Name: N-({(4R,7S,10S,13R,16R,19R)-10-(4-Aminobutyl)-16-(4-hydroxybenzyl)-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-[(N-{[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetyl}-D-phenylalanyl)amino]-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)threonine
CAS Number: 177943-88-3
Molecular Formula: C₆₅H₉₀N₁₄O₁₉S₂
Molecular Weight: 1435.623
Catalog: Signaling Pathways Others Others
Create Date: 2021-01-08 19:09:17
Modify Date: 2024-01-02 12:21:19
DOTATATE, a DOTA-conjugated peptide, and can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide therapy (PRRT)[1][2][3][4].

Name	N-({(4R,7S,10S,13R,16R,19R)-10-(4-Aminobutyl)-16-(4-hydroxybenzyl)-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-[(N-{[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetyl}-D-phenylalanyl)amino]-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)threonine
Synonyms	N-({(4R,7S,10S,13R,16R,19R)-10-(4-Aminobutyl)-16-(4-hydroxybenzyl)-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-[(N-{[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetyl}-D-phenylalanyl)amino]-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)threonine Threonine, N-[[(4R,7S,10S,13R,16R,19R)-10-(4-aminobutyl)-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-[[(2R)-1-oxo-3-phenyl-2-[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]propyl]amino]-1,2-dithia-5,8,11,14,17-pentaazacycloeicos-4-yl]carbonyl]-

Description	DOTATATE, a DOTA-conjugated peptide, and can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide therapy (PRRT)[1][2][3][4].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
In Vivo	177Lu-DOTATATE shows excellent antitumor effects in rats[1].
References	[1]. Jong M, et, al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S. [2]. Gains JE, et, al. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. Nucl Med Commun. 2020 Aug 10. [3]. Breeman WAP, et, al. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):917-20. [4]. Reubi JC, et, al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000 Mar;27(3):273-82.